KR102017354B1 - 트랜스타이레틴―관련 아밀로이드증에 대한 신규 치료법 - Google Patents

트랜스타이레틴―관련 아밀로이드증에 대한 신규 치료법 Download PDF

Info

Publication number
KR102017354B1
KR102017354B1 KR1020147010767A KR20147010767A KR102017354B1 KR 102017354 B1 KR102017354 B1 KR 102017354B1 KR 1020147010767 A KR1020147010767 A KR 1020147010767A KR 20147010767 A KR20147010767 A KR 20147010767A KR 102017354 B1 KR102017354 B1 KR 102017354B1
Authority
KR
South Korea
Prior art keywords
ttr
formula
pharmaceutically acceptable
comt
transthyretin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147010767A
Other languages
English (en)
Korean (ko)
Other versions
KR20140090161A (ko
Inventor
마르크 센텔라스 카사도
라울 인사 보로나트
누리아 레이그 볼라노
누리아 가발다 바탈라
Original Assignee
솜 이노베이션 바이오테크, 에스.엘.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47076222&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102017354(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 솜 이노베이션 바이오테크, 에스.엘. filed Critical 솜 이노베이션 바이오테크, 에스.엘.
Publication of KR20140090161A publication Critical patent/KR20140090161A/ko
Application granted granted Critical
Publication of KR102017354B1 publication Critical patent/KR102017354B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/603—Salicylic acid; Derivatives thereof having further aromatic rings, e.g. diflunisal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020147010767A 2011-10-24 2012-10-23 트랜스타이레틴―관련 아밀로이드증에 대한 신규 치료법 Active KR102017354B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11382326.4 2011-10-24
EP11382326 2011-10-24
PCT/EP2012/070945 WO2013060668A1 (en) 2011-10-24 2012-10-23 New therapy for transthyretin-associated amyloidosis

Publications (2)

Publication Number Publication Date
KR20140090161A KR20140090161A (ko) 2014-07-16
KR102017354B1 true KR102017354B1 (ko) 2019-09-02

Family

ID=47076222

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147010767A Active KR102017354B1 (ko) 2011-10-24 2012-10-23 트랜스타이레틴―관련 아밀로이드증에 대한 신규 치료법

Country Status (19)

Country Link
US (5) US9610270B2 (enExample)
EP (1) EP2770988B1 (enExample)
JP (1) JP6068484B2 (enExample)
KR (1) KR102017354B1 (enExample)
CN (1) CN103889407B (enExample)
AU (2) AU2012327275B2 (enExample)
BR (1) BR112014009322B1 (enExample)
CA (1) CA2852808C (enExample)
CL (1) CL2014000893A1 (enExample)
CY (1) CY1118151T1 (enExample)
ES (1) ES2593038T3 (enExample)
IL (1) IL231907B (enExample)
MX (2) MX347784B (enExample)
PL (1) PL2770988T3 (enExample)
PT (1) PT2770988T (enExample)
RU (2) RU2623062C2 (enExample)
SG (2) SG10201609933WA (enExample)
WO (1) WO2013060668A1 (enExample)
ZA (1) ZA201402546B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2770988T (pt) * 2011-10-24 2016-09-05 Som Innovation Biotech S L Nova terapêutica para a amiloidose associada à transtirretina
EP3185957B1 (en) * 2014-08-29 2022-06-01 Alnylam Pharmaceuticals, Inc. Patisiran for use in treating transthyretin mediated amyloidosis
EP3275433A1 (en) * 2016-07-29 2018-01-31 Som Innovation Biotech S.L. Sustained release composition comprising micronized tolcapone
EP3765003A4 (en) * 2018-03-12 2022-01-26 Corino Therapeutics, Inc. COMBINATION THERAPY FOR TTR AMYLOIDOSIS
BR112021024151A2 (pt) * 2019-05-31 2022-02-08 Plex Pharmaceuticals Inc Agentes farmacológicos para tratamento de doenças de agregação de proteínas do olho
CN114324693B (zh) * 2022-01-14 2023-01-13 大连博源医学科技有限公司 一种血液中转甲状腺素蛋白(ttr)四聚体浓度测定的预处理方法和检测方法
WO2024081554A2 (en) * 2022-10-10 2024-04-18 Corino Therapeutics, Inc. Modified release tolcapone formulations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005112913A1 (en) 2004-05-20 2005-12-01 The Scripps Research Institute Transthyretin stabilization

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744368A (en) 1993-11-04 1998-04-28 Research Foundation Of State University Of New York Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR)
WO1998027972A2 (en) 1996-12-23 1998-07-02 Texas A & M University Anti-amyloidogenic agents
FI20002044A0 (fi) 2000-09-15 2000-09-15 Orion Yhtymae Oyj Comt-entsyymiä estäviä naftaleenijohdannaisia
DK1372682T3 (da) 2001-03-15 2012-08-20 Proteotech Inc Catechiner til behandling af fibrillogenese ved alzheimers sygdom, parkinsons sygdom, systemisk AA amyloidose og andre amyloide forstyrrelser
WO2003063880A1 (en) 2002-01-29 2003-08-07 Protemix Corporation Limited Disruption of islet amyloid by polycyclic compounds
US20040175382A1 (en) 2003-03-06 2004-09-09 Schafer Peter H. Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
CN1921856A (zh) * 2004-02-20 2007-02-28 诺瓦提斯公司 用于治疗神经变性疾病和认知障碍的dpp－iv抑制剂
AU2005215136A1 (en) 2004-02-20 2005-09-01 Novartis Ag DPP-IV inhibitors for treating neurodegeneration and cognitive disorders
CN101035541B (zh) 2004-08-30 2012-05-30 柳署弘 溶解的udca在局灶缺血模型中的神经保护作用
GB2429645A (en) 2006-03-10 2007-03-07 Sekhsaria Chemicals Ltd Solid pharmaceutical composition comprising a COMT inhibitor, a starch and a wetting agent
US20120016037A1 (en) 2006-07-24 2012-01-19 Frank Toppo Method for prevention and treatment of Alzheimers
GB0718718D0 (en) 2007-09-25 2007-11-07 Pentraxin Therapeutics Ltd Compound and use thereof
DE102010010572A1 (de) 2010-03-08 2011-09-08 Mahle International Gmbh Trockenseparator
PT2770988T (pt) * 2011-10-24 2016-09-05 Som Innovation Biotech S L Nova terapêutica para a amiloidose associada à transtirretina

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005112913A1 (en) 2004-05-20 2005-12-01 The Scripps Research Institute Transthyretin stabilization
US20050282780A1 (en) 2004-05-20 2005-12-22 Richard Labaudiniere Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding

Also Published As

Publication number Publication date
AU2012327275A1 (en) 2014-04-17
IL231907B (en) 2018-05-31
US20170304243A1 (en) 2017-10-26
BR112014009322A2 (pt) 2017-04-18
US20190091188A1 (en) 2019-03-28
SG11201401215VA (en) 2014-08-28
RU2747536C2 (ru) 2021-05-06
US20140296188A1 (en) 2014-10-02
CA2852808C (en) 2021-07-06
US9610270B2 (en) 2017-04-04
MX385516B (es) 2025-03-18
MX2014004863A (es) 2014-05-27
HK1198432A1 (en) 2015-04-24
MX347784B (es) 2017-05-12
CL2014000893A1 (es) 2014-09-05
AU2012327275A2 (en) 2014-04-17
PL2770988T3 (pl) 2017-01-31
BR112014009322A8 (pt) 2018-01-16
US10786473B2 (en) 2020-09-29
RU2623062C2 (ru) 2017-06-21
IL231907A0 (en) 2014-05-28
AU2017202670B2 (en) 2019-06-06
US20200138760A1 (en) 2020-05-07
NZ623267A (en) 2015-11-27
US10045956B2 (en) 2018-08-14
CN103889407A (zh) 2014-06-25
AU2017202670A1 (en) 2017-05-11
CY1118151T1 (el) 2017-06-28
US10449169B2 (en) 2019-10-22
RU2017119539A (ru) 2018-11-09
ZA201402546B (en) 2015-07-29
JP6068484B2 (ja) 2017-01-25
SG10201609933WA (en) 2017-02-27
BR112014009322B1 (pt) 2022-05-10
RU2017119539A3 (enExample) 2020-06-29
PT2770988T (pt) 2016-09-05
RU2014114930A (ru) 2015-12-10
WO2013060668A1 (en) 2013-05-02
CN103889407B (zh) 2017-03-15
US11564899B2 (en) 2023-01-31
EP2770988B1 (en) 2016-07-20
EP2770988A1 (en) 2014-09-03
US20200390733A1 (en) 2020-12-17
CA2852808A1 (en) 2013-05-02
JP2014530842A (ja) 2014-11-20
AU2012327275B2 (en) 2017-03-02
KR20140090161A (ko) 2014-07-16
ES2593038T3 (es) 2016-12-05

Similar Documents

Publication Publication Date Title
KR102017354B1 (ko) 트랜스타이레틴―관련 아밀로이드증에 대한 신규 치료법
JP4500543B2 (ja) 筋萎縮性側索硬化症を処置するためのプラミペキソールの使用
KR100676124B1 (ko) 엔-[2-히드록시-3-(1-피페리디닐)프로폭시]피리딘-1-옥사이드-3-카르복시미도일 클로라이드 및 인슐린 내성 치료에 있어서의 이의 용도
JP2005516911A6 (ja) 筋萎縮性側索硬化症を処置するためのプラミペキソールの使用
JP2023500919A (ja) 関節炎の処置
TWI472519B (zh) 含正－亞丁基苯酞之醫藥組成物用於治療肝損傷及改善肝功能
KR930010583B1 (ko) 신기능 증진 효과 및 이뇨 효과를 갖는 약제
NZ623267B2 (en) New therapy for transthyretin-associated amyloidosis
HK1198432B (en) Therapy for transthyretin-associated amyloidosis
US20210069139A1 (en) Stabilization of transthyretin tetramers in biological fluids
AU2006289752B2 (en) Combination drug containing probucol and a tetrazolylalkoxy-dihydrocarbostyril derivative with superoxide supressant effects

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 7